AHRQ Rx Comparisons Should Focus On Existing Literature, Not Clinical Trials, McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trials take too much time and money, CMS Administrator McClellan says. Programs mandated under Medicare Rx law, such as the chronic care improvement pilot and the Part B replacement drug demo, will provide clinical data to evaluate comparative effectiveness, he says.
You may also be interested in...
AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says
The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.
AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says
The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.
AHRQ Rx Comparative Research Partners Include CMS, NIH, FDA, VA, McClellan Says
CMS administrator says NIH can develop comparative evidence based on clinical trial databases and keep CMS apprised of drugs being studied. Speakers at AHRQ comparative research “town hall” point to public, private and international purchasers that could provide comparative drug information.